President Donald Trump announced a major pricing deal Friday with AstraZeneca, which agreed to offer its catalog of prescription drugs to the United States at discounted prices under the “most-favored nation” (MFN) policy, aligning U.S. prices for Medicaid patients with the lowest prices in other developed countries.
This marks the second such deal that the Trump administration has negotiated. The first was with Pfizer. In both cases, the deal involved lower prices in the U.S., major investments in American-based research and production, and potential tariff relief, according to CNBC.Â
The AstraZeneca agreement is expected to be available to all State Medicaid programs and will be published on a new government website, TrumpRx.gov, according to a White House Fact Sheet published Friday.Â
The company announced that it will invest $50 billion in U.S. manufacturing and research and development by 2030. President Trump announced that they are building a new facility in Charlottesville, Virginia, “which will produce advanced pharmaceutical ingredients to support their chronic disease and oncology pipelines,” and the facility will create 3,600 highly skilled jobs.
According to the fact sheet, “9 million American patients are treated by AstraZeneca medicines and will benefit from the President’s successful negotiation to lower prices.”
